Newsletter · 2026-09-04 · Ashutosh Agarwal

Biotech Rips Higher on Moderna's Cancer Vaccine While Insurers Cut a Million Members - Healthcare Podcast Weekly Digest - Week of September 4, 2026

Healthcare Podcast Weekly Digest for August 29 to September 4, 2026: the XBI is up about 80 percent in twelve months on a deal wave, a calmer FDA and a Moderna and Merck cancer-vaccine win, while Lilly pulls away from Novo in GLP-1s and the two largest insurers drop more than a million Medicare Advantage members.

Healthcare Podcast Weekly Digest

Week of September 4, 2026: Biotech Rips Higher on Moderna's Cancer Vaccine While Insurers Cut a Million Members

What portfolio managers, analysts, and executives said on the podcasts this week about healthcare stocks, with the numbers, the names, and the reasoning behind each view.

The week in one read

Healthcare had a genuinely remarkable stretch, and the podcasts spent most of their oxygen on why. The biotech index (the XBI, an exchange-traded fund that tracks smaller drug developers) is up about 80% over the past 12 months, against roughly 20% for the S&P 500, and a big chunk of that came in a single month. Three things are driving it: a wave of dealmaking, an FDA that has calmed down after a chaotic year, and a string of real scientific wins, led by a Moderna and Merck cancer vaccine that sent Moderna's stock up nearly 200% in a day.

A recurring phrase this week was the "anti-AI trade." With technology stocks wobbling, money is rotating into a sector that had been left for dead, and several analysts argued the move still has room to run because healthcare valuations are cheap and Washington just took a major worry off the table. On Aug 31, the Trump administration announced drug-pricing deals with nine more drugmakers, bringing the total to 26 companies and easing years of fear about a government overhaul of drug prices.

But it was not all celebration. The GLP-1 weight-loss story is maturing in ways that matter: Eli Lilly is pulling decisively ahead of Novo Nordisk (whose stock is down about 70% from its 2024 peak), the new pills are ramping unevenly, and Lilly's much-hyped launch in India has hit a wall. Meanwhile, health insurers are in a painful reset, more than a million Medicare Advantage members are being dropped by the two largest carriers for 2027, and UnitedHealth is under a Justice Department probe over how it codes patient diagnoses.

Below: who said what, the biggest debates, the deals, and what to watch next week.

Key people this week

Hot topics

1. Moderna's cancer vaccine, the trade that defined the month

This was the story every investing podcast came back to. On Aug 19, Moderna and Merck reported that their personalized mRNA cancer vaccine, given with Merck's Keytruda, worked in a large Phase 3 trial of high-risk melanoma patients, the cancer was less likely to return or spread. (A personalized vaccine means each patient's own tumor is sequenced and a custom shot is manufactured for them.)

The market reaction was violent. On Biotech Hangout (Aug 28), Sam Fazeli described it plainly:

"The stock was trading around the $50, $60 range for about six months. And then on the day, August 19th, we're looking at $170. It closed at just over $170... and now it's settled around $140 range." Sam Fazeli, Biotech Hangout

Fazeli's team models the vaccine at about $12 billion in peak sales if everything works (not risk-adjusted), with roughly half shared with Merck. BioSpace (Aug 26) reported analysts pegging peak sales at about $2 billion for melanoma alone and about $5.6 billion across tumor types, split 50/50, and noted Merck's own shares jumped 12%, a large move for a company that size, as investors finally saw a growth story to replace Keytruda when it loses patent protection around 2028.

On The Journal. (Aug 28), a Wall Street Journal reporter described the scene inside Moderna when the results came in "sooner than anyone thinks," with staff crying and hugging over champagne. CEO Stéphane Bancel, reading from a note card so he wouldn't choke up, put it bluntly: "We are now an oncology company." The trial ran in over 1,000 patients; the companies will present exact numbers at a medical conference later this year and hope for FDA approval in 2027.

One under-appreciated angle from Biotech Hangout: Eric Schmidt pointed out that because Moderna keeps its neoantigen-selection algorithm a trade secret, there may never be a generic version, potentially "a forever franchise." The same week, rival BioNTech's colorectal-cancer vaccine trial was stopped for futility, drawing a rough line between "hot" tumors (melanoma, where the approach worked) and "cold" ones (colorectal, where it struggled).

2. Revolution Medicines, a rare win in pancreatic cancer

On Squawk on the Street (Aug 27), Revolution Medicines CEO Dr. Mark Goldsmith walked through the FDA approval of Razon-Q (daraxonrasib), the first targeted medicine for metastatic pancreatic cancer that hits the disease's main cause, a protein family called RAS. The numbers are striking for one of the deadliest cancers:

• Median survival extended from 6.7 months to 13.2 months, a 60% reduction in the risk of death.
• About 55,000 new metastatic pancreatic cancer cases a year in the US.
• Price: about $40,000 for 30 days (roughly $478,000 a year). Goldsmith said the price "reflects the differentiation and very meaningful benefit," and pointed to a patient-support program.
• RAS proteins also drive 30% of lung cancers and 50% of colorectal cancers, with Phase 3 trials pending, the real prize.

The FDA cleared it in about a month using a priority voucher. On Biotech Hangout, Eric Schmidt (a former board member) called it "remarkable execution," while Sam Fazeli flagged the sticker shock and "financial toxicity" concerns. UBS's Michael Yee named it a top pick, and Health:Further's hosts framed it as hope for a disease where oncologists "over and over" deliver bad news.

3. GLP-1 weight-loss drugs, Lilly pulls away, Novo stumbles, India stalls

The obesity-drug race is no longer a two-horse dead heat. Web and podcast reporting this week put Eli Lilly at about 60% of the US GLP-1 market versus Novo Nordisk at about 39%, with Lilly guiding to $82 billion to $85 billion in 2026 revenue.

• Novo Nordisk's stock is down about 70% from its June 2024 peak. On Health:Further (Aug 29), the hosts were incredulous: "This was the blockbuster drug of the decade... and their stock is down 70%... Lily has really beat them." They called it a future Harvard Business School case in "bag fumbling."
• The oral pills are ramping unevenly. Novo's Wegovy pill reached about 175,000 weekly prescriptions (about 35% of Wegovy scripts); Lilly's Foundayo (orforglipron) did $98M in Q2 and more than 40,000 weekly prescriptions, a slower start, but it's a small molecule that's cheaper to make with no food or water restrictions. Lilly launched Foundayo in the UK this week at £100 to £120 a month.
• India is a cautionary tale. On Daybreak (Sep 1), The Ken reported that after 50-plus generics launched in March, a Nomura forecast of $260M in 2026 sales was only about 20% met by July; monthly sales growth collapsed from 58.4% in April to about 2% in June. The Lilly and Cipla product "Your Peak" runs 12,000 to 24,000 rupees a month, 10% to 60% of a middle-class household's income. For scale: Ozempic did about $12 billion in the US in 2025; India's entire GLP-1 market is about $220 million to $230 million, "Ozempic's US market alone earns India's entire annual GLP-1 market in about a week."

Lilly CEO David Ricks, interviewed at the G20 on Squawk on the Street (Aug 31), framed the long game: about 25 million to 30 million people globally are on these drugs today against more than a billion potential customers. On employers like PepsiCo dropping coverage, he pushed back: "You're already paying for obesity, whether you cover the drugs or not," citing a Lilly study showing ZepBound was "more than break even" by 12 months.

4. Managed care, a brutal reset for health insurers

Investors don't often listen to insurance-broker podcasts, but this week The Broker Link (Sep 1) laid out the 2027 Medicare Advantage landscape in unusual detail (Medicare Advantage is the private version of Medicare that insurers run for the government):

• WellCare/Centene lost nearly $1 billion in 2023 and 2024 and is terminating 92 plans, about 32% of its membership, over 300,000 members, targeting break-even by 2027. It's leaning into Medicaid-linked "dual eligible" plans and accepting that it will operate some three-star plans.
• UnitedHealthcare lost nearly 1 million members last enrollment season but had record win-backs afterward, growing "more than any other carrier" by July. It's shifting away from PPOs toward HMOs and dual-eligible plans.
• Humana is dropping about 600,000 members even after a banner year (+24% growth, 1.3M new members).
• Combined, the two largest carriers alone are cutting over a million members. The one bright spot: hosts said 2026 medical-cost trends are "flattening," margins are recovering, and "there's a light at the end of the tunnel."

The bigger-picture policy read came from Emily Evans of Hedgeye on Healthcare Nation (Aug 25). Asked what the market is mispricing, she answered "nearly everything," and argued that a redesign of Medicare's Part D drug benefit, plus the end of a Biden-era premium subsidy, will push standalone drug-plan premiums up sharply, triggering an "adverse selection" spiral where only sick, high-cost patients stay enrolled. On the biggest managed-care names she was blunt: "I am very negative on Medicare Advantage," singling out Centene, Molina, UnitedHealth, and Elevance as most exposed to looming Medicaid work requirements.

5. Medtronic and the "boring is good" pharma trade

On Halftime Report (Aug 28), the CNBC Investment Committee debated Medtronic ahead of earnings. Kevin Simpson liked the momentum and demographic tailwind ("as we baby boomers age, we become... potential customers"). Jenny Harrington framed it as a "de-risked" value play, 15x earnings, a 7% free-cash-flow yield, down 5% year-to-date, the kind of name "where you don't need to worry about AI." Jim Lebenthal preferred pharmaceuticals outright: AbbVie, AstraZeneca, and Vertex on valuation; Harrington's final pick was Pfizer ("6% dividend yield, nine times earnings").

Key debates

Can the biotech rally keep going?

• Bulls: UBS's Michael Yee, the sector is "so cheap, so underappreciated," with "a striking amount of good news and M&A"; charts are breaking out. RBC notes 58% of surveyed investors still expect biotech to beat the S&P in the second half, with a record-low 8% expecting underperformance.
• Bears and cautious: RBC's Brian Abrams warns the rally is "real" but the sector "hasn't completely de-risked," valuations have run up, only 22% of investors still see biotech as undervalued (down from 52% six months ago), and in the three prior times the XBI beat the S&P by 15% or more this fast, forward returns were "more mixed." Hedgeye's Emily Evans is outright bearish, arguing cheap money spawned too many biotechs with weak trial records.

Is the Moderna move justified?

• Believers: The Journal framed it as a decade-long platform bet finally paying off, with a potential "forever franchise" in personalized vaccines.
• Skeptics: On Biotech Hangout, Eric Schmidt noted "a lot of people are still struggling to see how so much value was created... based on this one melanoma result," and whether it translates to other tumors. Verdad's Dan Rasmussen is short the stock.

AI in drug discovery, real driver or story?

• Skeptic: Verdad's Dan Rasmussen: the idea AI will drive drug development is "somewhat far-fetched"; the real fuel is M&A and genuine science. Hedgeye's Emily Evans: "AI is not going to cure cancer... What AI is going to do is create the tools for the people who are going to... treat and cure disease."
• Believer: Lilly CEO David Ricks flew to the G20 specifically to speak on an AI panel about how it's changing the business.

Medicare Advantage, bottomed or more pain ahead?

• Turning: Broker Link hosts and CMS chatter point to flattening medical costs and recovering margins in 2026, "we've seen the worst of it."
• More pain: Emily Evans stays "very negative," citing rural-hospital tensions and the Part D premium shock; over a million members are being cut for 2027.

GLP-1 coverage, who pays? Lilly's Ricks argues covering the drugs is the "smart financial move." But employers (PepsiCo) are dropping coverage, some Medicaid states are opting out of subsidized programs, and India shows how fast demand stalls without insurance and cultural buy-in.

Emerging themes

• "Anti-AI trade." Multiple analysts (UBS's Yee, Verdad's Rasmussen, RBC) described healthcare and biotech as the destination for money rotating out of volatile AI and tech names, a defensive bet on cheap valuations and real cash flows.
• Personalized cancer vaccines as a new asset class. BioSpace called Moderna and Merck "the first Phase 3 validation" of the approach, with several rivals in the pipeline, a template investors will now underwrite.
• Lilly's "many small bets" M&A model. Bloomberg Intelligence's Michelle Tesoro: Lilly reviews about 10 deals a week, keeps them small (largest ever under $8B), and develops in-house where it can, a deliberate contrast to peers doing $25 billion to $50 billion mega-mergers. Ricks: "They are just chucking a lot of potatoes."
• Policy as a leading market indicator. Healthcare Nation's whole thesis: a reimbursement tweak in Washington "doesn't remain a policy decision for very long," it moves through plans, hospitals, and drugmakers before Wall Street prices it.
• Direct-to-consumer drugs. Emily Evans flagged GLP-1 makers selling straight to patients (via Lilly's own channel), "cutting out PBMs and wholesalers," a structural change she thinks Wall Street is underrating.
• GLP-1s as an economic force. Ricks argued the drugs are "one of the few things... to curb the growth of entitlement spending," with winners (fitness, lifestyle) and losers (alcohol, salty foods) rippling out over time.

Deals & M&A tracker

• Eli Lilly to acquire Merida Biosciences, up to $2.88 billion in cash (announced Aug 31). An early-stage (Phase 1) "degrader" play in autoimmune and allergic disease; lead program MER511 targets Graves' disease and thyroid eye disease. Expected to close Q4 2026. Lilly shares dipped about 1.3% on the news. It caps more than $25 billion in announced Lilly deals year-to-date (Ricks, Squawk on the Street).
• Biotech M&A running hot: about $78 billion in cumulative deal value by mid-year (nearly 2x all of 2025) per RBC; about $138 billion announced year-to-date per Biotech Hangout. The driver: roughly $400 billion of large-pharma revenue at risk from patent expirations over the next decade, against more than $180 billion of pharma free cash flow to spend. RBC thinks the pace slows in H2 as natural buyers (Vertex, Gilead, AbbVie, Biogen) digest deals.
• AstraZeneca and Bristol Myers "mega-merger" was floated in the press; RBC's US pharma analyst assigns it a low probability.
• Genentech/Roche and Hanmi obesity deal (about $190M upfront) referenced on BioCentury as part of big pharma's push into metabolic disease.

Regulatory watch

• Drug-pricing deals, round 2 (Aug 31): The Trump administration announced Most-Favored-Nation pricing agreements with 9 more drugmakers (Teva, Sun Pharma, Astellas, Kyowa Kirin, CSL, UCB, Alcon, BridgeBio, BeOne), bringing the total to 26 companies, reportedly about 89% to 90% of the US branded market. Deals discount Medicaid prices toward the lowest in developed markets. Analysts (UBS's Yee) see this as a net positive: it removes uncertainty without an onerous overhaul.
• Pharma tariffs: Section 232 tariffs of up to 100% on imported patented drugs are phasing in, with a hard deadline of Sept 29, 2026 for remaining importers. Companies that sign both a pricing deal and a US-onshoring plan get a 0% rate through Jan 2029. Ricks noted the new tariffs mostly hit generics and are "pushed out a few years."
• FDA leadership: President Trump nominated Dr. Heidi Overton (White House Domestic Policy Council, surgeon, Johns Hopkins PhD) as permanent FDA commissioner. Analysts on BioSpace expect confirmation is unlikely before the midterms and don't expect her to "rock the boat"; seen as favorable for psychedelic and non-opioid pain therapies.
• Approvals flurry: Mounjaro cleared to reduce cardiovascular risk in high-risk type 2 diabetics (Aug 28, shares +1.1%); Roche and Lilly's Elecsys pTau217 Alzheimer's blood test cleared for adults 55+ (Aug 24); the RevMed pancreatic approval (above); plus the first mRNA flu shot and Abbott glucose/ketone sensors noted on clinical podcasts.
• Medicare billing: Humana's VillageMD unit agreed to a $542 million settlement over Medicare Advantage overbilling, on Health:Further, hosts noted diagnosis codes were allegedly added "without seeing the patient." Separately, UnitedHealth remains under a DOJ civil and criminal probe into its Medicare Advantage risk-adjustment coding (web-sourced; UNH says it is complying and launched an independent audit).
• Part D redesign: The first CMS-negotiated Maximum Fair Prices took effect Jan 1, 2026 on 10 Part D blockbusters; the end of a Biden-era premium subsidy is expected to push standalone drug-plan premiums higher (Hedgeye's Evans).
• Analyst action: UnitedHealth was downgraded to Hold from Buy at Erste Group (Aug 27) on below-sector revenue growth and a premium valuation. Rothschild & Co Redburn nudged its Lilly target to $930 (Neutral); the broader FactSet-polled consensus is Overweight with a mean target near $1,349.

Week ahead

• Cantor Fitzgerald Global Healthcare Conference, Sept 9 to 11 (NYC) and H.C. Wainwright Global Investment Conference, Sept 14 to 16. Expect a wave of management updates and pipeline commentary from small- and mid-cap names.
• A dense FDA decision window across oncology, neurology, and rare disease, names flagged include Ionis (IONS), Mirum (MIRM), and Ultragenyx (RARE).
• Phase 3 readouts in targeted oncology and cardiac drugs are expected through late September, ahead of the ESMO cancer congress in October, a likely source of the next scientific catalyst.
• Watch the "anti-AI rotation": if technology stays choppy, RBC and UBS both expect continued fund flows into healthcare, but with more selectivity than the first-half melt-up.
• Managed care 2027 plan details keep rolling out; the scale of member terminations (1M-plus from the two largest carriers) will shape the fall enrollment season and insurers' 2027 margin math.